Gencurix Inc.
KOSDAQ 229000.KQ
Gencurix Inc. Price to Book Ratio (P/B) on January 14, 2025: 1.75
-
Gencurix Inc. 52-week high Price to Book Ratio (P/B) is 6.33 on January 17, 2024, which is 261.24% above the current Price to Book Ratio (P/B).
-
Gencurix Inc. 52-week low Price to Book Ratio (P/B) is 1.21 on December 09, 2024, which is -31.18% below the current Price to Book Ratio (P/B).
-
Gencurix Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 3.18.
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
| CEO | Sung-Rai Cho |
| IPO Date | April 5, 2017 |
| Location | South Korea |
| Headquarters | Hanhwa Bizmetro |
| Employees | 69 |
| Sector | Health Care |
| Industries | |
Gencurix Inc. provide diagnostic solutions in South Korea. Its products include GenesWell BCT, a prognosis diagnostic test for breast cancer; GenesWell ddEGFR Mutation Test, a companion test for lung cancer; Droplex, a genetic test that detects DNA mutations; eDX, an early diagnosis for cancer with liquid biopsy; GenePro COVID-19 detection test; GenePro SARS-CoV-2 Test kit; GenoCTC (circulating tumor cell isolator); GenePro LAMP test solution for rapid, convenient and simple detection of various infectious diseases; and GenePro LAMP Cycler, a device for loop-mediated isothermal amplification. The company was founded in 2011 and is headquartered in Seoul, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email